S

Sanofi

Global pharma company; vaccines and R&D

Junior Analyst Transparency Reporting

Full-TimeUpdated on 10/15/2026Deadline 12/13/26
HUF6.3M - HUF9.5M
Entry
Bachelor's
Budapest, Hungary
Hybrid
Risk & ComplianceRegulatory Compliance & Ethics

About the job

Requirements
  • A bachelor's degree from an accredited college or university in a relevant field, such as life sciences, business, finance, or data/analytics.
  • A recent graduate profile is welcomed.
  • Familiarity with basic data collection and quality-check practices gained through academic work, internship, or equivalent experience.
  • Fluency in English and Italian, written and verbal, is essential.
  • Beginner-level strategic thinking, results orientation, critical thinking, collaborative communication, stakeholder relationship management, and ability to influence others.
  • Detail-oriented and organized, with a disciplined approach to documentation and file version control.
  • Comfort working in an international matrix environment across time zones, markets, and dual-reporting structures.
  • Ability to accept constructive feedback and integrate it on an ongoing basis.
Responsibilities
  • Collect and consolidate transfers-of-value data from multiple source systems and business functions across supported markets, following defined collection processes.
  • Perform first-level data quality checks for completeness, accuracy, and duplicates before country-level submission.
  • Support data control activities under the close guidance of senior analysts.
  • Flag data anomalies and assist in root-cause investigation and remediation.
  • Maintain accurate documentation and evidence of data collection and control activities for audit purposes.
  • Apply foundational knowledge of EFPIA Disclosure Code principles to the classification and reporting of transfers-of-value data across assigned markets.
  • Support country-level transparency reporting activities and requirements in partnership with the relevant in-country transparency teams.
  • Build working knowledge of country-specific transparency regulation across supported markets.
  • Escalate regulatory questions and updates to the Transparency Team Lead in a timely manner.
  • Assist in preparing country disclosure reports and supporting reconciliation files.
  • Support report validation and quality assurance activities under senior analyst supervision.
  • Help ensure data readiness for disclosure submissions according to country-specific timelines.
  • Contribute to preparing basic tracking dashboards and monitoring reports for the Global Sources team.
  • Maintain audit-ready documentation across assigned reporting and data collection activities.
  • Liaise with in-country stakeholders across supported markets to clarify data queries and support timely reporting cycles.
  • Communicate basic data requirements and deadlines to data providers under guidance from senior team members.
  • Escalate unresolved data issues to senior analysts or the Transparency Team Lead in a structured manner.
  • Participate in knowledge-sharing sessions and training to progressively build autonomy within the team.
  • Demonstrate Company values and Take the Lead ways of working.
Desired Qualifications
  • Prior internship experience in transparency, compliance, or healthcare regulatory reporting is a strong plus.
  • Initial exposure to EFPIA Disclosure Code principles and/or country-specific transparency operations, such as Sanità Trasparente in Italy, is a plus.
  • Advanced Microsoft Excel, Power BI, SQL, and Python are preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...